 |
|
|
| |
Bristol-Myers Squibb HCV DAAs: Review of Interactions Involving Transporters
|
| |
| |
"Daclatasvir (DCV, BMS-790052)......Currently under FDA review as part of a combination regimen for HCV with ASV and in Phase 3 as part of an all-oral regimen with ASV and BMS-791325.....DCV has no clinically meaningful interactions with transplant (prevention of organ rejection) medications....No clinically meaningful interaction between ASV and DCV" also phase 3 ongoing with daclatasvir+sofosbuvir including in HIV/HCV coinfected, gt3, cirrhotics, post-liver transplant
Daclatasvir+Sofosbuvir - (05/09/14)
--------------------
Reported by Jules Levin
15th International Workshop on Clinical Pharmacology of HIV and Hepatitis Therapy, May 19-21, 2014, Washington, DC
Timothy Eley
15th HIV/HEPPK Workshop
21 May 2014
-------------------------
15th International Workshop on Clinical Pharmacology of HIV and Hepatitis Therapy
May 19- 21, 2014, Washington, DC
Single-Dose Pharmacokinetics of Daclatasvir (DCV; BMS-790052) in Subjects With Hepatic Impairment (Child-Pugh A/B/C) Compared With Healthy Subjects......http://www.natap.org/2011/AASLD/AASLD_78.htm.....Bifano AASLD 2011
Daclatasvir (DCV; BMS-790052) Has No Clinically Significant Effect on the Pharmacokinetics of a Combined Oral Contraceptive Containing Ethinyl Estradiol and Norgestimate in Healthy Female Subjects.......http://www.natap.org/2011/AASLD/AASLD_77.htm Bifano AASLD 2011
CROI/2012: Assessment of HIV Antiretroviral Drug Interactions With the HCV NS5A Replication Complex Inhibitor Daclatasvir Demonstrates a PK Profile Which Supports Coadministration With Tenofovir, Efavirenz and Atazanavir/r http://www.natap.org/2012/CROI/croi_38.htm
Effect of Hepatic Impairment on the Pharmacokinetics of Asunaprevir (BMS-650032, ASV)........http://www.natap.org/2012/AASLD/AASLD_65.htm......AASLD 2012
Evaluation of Pharmacokinetic Drug-Drug Interaction (DDI) Between BMS-791325, an NS5B Non-Nucleoside Polymerase Inhibitor, Daclatasvir and Asunaprevir in Triple Combination in HCV Genotype 1-Infected Patients........http://www.natap.org/2013/EASL/EASL_11.htm .....EASL Amsterdam April 25, 2013
Coadministration of BMS-790052 and BMS-650032 Does Not Result in a Clinically Meaningful Pharmacokinetic Interaction in Healthy Subjects......AASLD Nov 2 2010.......http://www.natap.org/2010/AASLD/AASLD_64.htm
Exposure-Response Analyses of Asunaprevir in Combination With Daclatasvir ± Peginterferon Alfa/Ribavirin Among Patients With Genotype 1 Chronic HCV Infection: Dose Selection for Phase 3 Clinical Trials.......http://www.natap.org/2013/EASL/EASL_42.htm.......EASL 2013
Safety, Tolerability, Pharmacokinetics and Antiviral Activity following Single- and Multiple-Dose Administration of BMS- 650032, a Novel HCV NS3 Inhibitor, in Subjects with Chronic Genotype 1 HCV Infection.....http://www.natap.org/2009/AASLD/AASLD_13.htm
Sofosbuvir and Daclatasvir for Recurrent Hepatitis C After Liver Transplantation: Potent Antiviral Activity But Lack of Clinical Benefit if Treatment is Given Too Late......http://www.natap.org/2014/EASL/EASL_54.htm
Sofosbuvir and Daclatasvir Combination Therapy in a Liver Transplant Recipient With Severe Recurrent Cholestatic Hepatitis C - (11/25/13)
-------------------------
|
| |
|
|
|
|
|
